eortc brain tumour group
Home  |  Members Area  |  Links  |  Disclaimer




ongoing trials

Members of the EORTC have access to the full protocol texts at
» www.eortc.be using their ORTA username and password

Protocol ID


EORTC 26101 Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma
EORTC 26091 Phase II randomized trial assessing the significance of bevacizumab in recurrent grade II and III gliomas
EORTC 26081 Phase II randomized trial assessing intergroup study of radiotherapy versus temozolomide versus radiotherapy with concomitant and adjuvant temozolomide for patients with newly diagnosed anaplastic oligodendroglioma or anaplastic mixed glioma with chromosomal co-deletions of 1p and 19q
EORTC 26083
Randomized phase II of CCNU versus CCNU-dasatinib in patients with recurrent glioblastoma
EORTC 26082-22081 Phase II open-label randomized study of radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemo-irradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter
EORTC 26053-22054
CATNON Intergroup Trial
(with RTOG, NCI-C, MRC, HUB)
Phase III randomized study of radiotherapy with or without concurrent and/or adjuvant temozolomide in patients with non-1p/19q deleted anaplastic glioma
Activated: December, 2007
EORTC 22042-26042
Phase II and observational study of adjuvant high-dose radiotherapy in patients who have undergone surgery for newly diagnosed grade II or III meningioma
Activated: 2008
EORTC 26062-22061,
Phase III randomized study of short-course radiotherapy with or without temozolomide in older patients with newly diagnosed glioblastoma multiforme
To be activated in Europe: mid 2008

Trials in preparation (2011):



go to top of page 

oben eortc homepage